Floatz logo

Aspirin

Cardiovascular Disorder

AstraZenecaSmall moleculePhase 4 / ApprovedDormant
BBB
78/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
71/ 100
Competitive Position
89/ 100

Competitive context

55 Active assets in the Cardiovascular Disorder cohort.

Asset / SponsorPhaseRating
ATORVASTATIN
Duke University
Phase 4BBB
Liraglutide
University of Sao Paulo General Hospital
Phase 4BBB
Rosuvastatin
Nanjing First Hospital, Nanjing Medical University
Phase 4BBB
SIMVASTATIN
McMaster University
Phase 4BBB
RAMIFENTANYL
Helse Fonna
Phase 4BBB

View all 50 →

Same molecule, other indications

Aspirin is also rated in:

myocardial infarctionActive
A
Indicative · Phase 4
83 / 100
View asset →
coronary artery disorderActive
BBB
Indicative · Phase 4
79 / 100
View asset →
transient ischemic attackActive
BBB
Indicative · Phase 4
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →